TASIGNA®

Hold Company

NOVARTIS

Learn More

Dosage and Administration

CAPSULE;ORAL

Specification

EQ 200MG BASE; EQ 150MG BASE; EQ 50MG BASE

Indication

TASIGNA® is used to treat adult and pediatric patients with Ph+ CML-CP.

Use

Instructions for Use

API

NILOTINIB HYDROCHLORIDE

API Structure

We Supply

NILOTINIB HYDROCHLORIDE

Note:

CP/EP/USP/In-house
Facility GMP
DMF/CEP/EMA

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
7169791*PED	2024/1/4
8163904	2028/8/23
8163904*PED	2029/2/23
8293756	2027/9/25
8293756*PED	2028/3/25
8389537	2026/7/18
8389537*PED	2027/1/18
8415363	2026/7/18
8415363*PED	2027/1/18
8501760	2026/7/18
8501760*PED	2027/1/18
9061029	2032/4/7
9061029*PED	2032/10/7

API Patent

Patent No	Expiration Date
7169791*PED	2024/1/4
8163904	2028/8/23
8163904*PED	2029/2/23
8389537	2026/7/18
8389537*PED	2027/1/18
8415363	2026/7/18
8415363*PED	2027/1/18

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.